6130.TWO Singbao International Co Ltd
- Market cap
- TWD 1.22B
- P/E
- -
- P/B
- 2.29x
- ROE
- -0.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 6130.TWO undervalued?
Graham numberThe Graham number of Singbao International Co Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Singbao International Co Ltd fundamental analysis
No fundamental analysis for Singbao International Co Ltd yet.
Singbao International Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Singbao International Co Ltd
Shangya Technology Co., Ltd. engages in the generic drugs and solar power generation businesses in Taiwan and Asia. The company wholesales Chinese and Western medicines, medical equipment, and beauty and hair care products; and onrito, lixin fumitation, lufuxing film-coated, amperex film coating, leverb-coated, triton film-coated, special core stabilized, tanlipo film-coated, inhibitory film-coated, yoyo flat mouth dissolved, and binlishu film-coated tablet, as well as pain …
Full company profileSingbao International Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Singbao International Co Ltd annual financial statements (TWD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 179M | 85.8M | 53.7M | 63.5M | 138M | 104M | 85.2M | 231M | 195M | 155M | 178M |
| Gross Profit | 48.3M | 12.8M | 6.53M | 23.6M | 90.0M | 46.7M | 34.2M | 61.2M | 69.2M | 46.5M | 69.2M |
| Operating Income | 3.71M | -13.3M | -26.7M | -15.8M | -18.6M | -16.1M | -23.8M | -7.74M | -35.5M | -73.9M | -17.0M |
| EBITDA | 14.1M | -4.64M | -16.4M | -4.93M | 961K | 515K | -6.08M | 22.9M | 5.87M | -49.2M | 14.5M |
| Net Income | 2.23M | -10.3M | -23.5M | -16.4M | -26.9M | 32.5M | 1.28M | -80.0M | -33.4M | -76.3M | -2.91M |
| EPS | 0.08 | -0.37 | -0.83 | -0.58 | -0.87 | 1.06 | 0.03 | -1.81 | -0.75 | -1.72 | -0.06 |
| Balance Sheet | |||||||||||
| Total Assets | 315M | 442M | 412M | 562M | 1.22B | 551M | 939M | 967M | 978M | 878M | 736M |
| Total Liabilities | 17.2M | 158M | 153M | 234M | 789M | 78.0M | 168M | 166M | 232M | 227M | 147M |
| Shareholders' Equity | 295M | 284M | 260M | 255M | 282M | 473M | 771M | 683M | 625M | 545M | 589M |
| Cash & Short-term Investments | 222M | 163M | 78.1M | 47.4M | 105M | 55.4M | 408M | 293M | 242M | 188M | 75.4M |
| Total Debt | 378K | 140M | 140M | 208M | 766M | 67.9M | 147M | 133M | - | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 26.5M | 6.60M | -55.3M | 9.67M | 21.9M | 2.50M | -17.3M | 269K | 11.3M | -44.2M | -47.1M |
| Capital Expenditure | 271K | 14.2M | 35.4M | 89.6M | 128M | 0.00 | 0.00 | 10.9M | 10.8M | 75.9M | 7.73M |
| Free Cash Flow | 26.2M | -7.61M | -90.7M | -80.0M | -106M | 2.50M | -17.3M | -10.7M | 454K | -120M | -54.8M |
| Ratios | |||||||||||
| ROE | 0.8% | -3.6% | -9.0% | -6.4% | -9.5% | 6.9% | 0.2% | -11.7% | -5.3% | -14.0% | -0.5% |
| ROA | 0.7% | -2.3% | -5.7% | -2.9% | -2.2% | 5.9% | 0.1% | -8.3% | -3.4% | -8.7% | -0.4% |
| Net Profit Margin | 1.3% | -12.0% | -43.7% | -25.9% | -19.5% | 31.3% | 1.5% | -34.6% | -17.1% | -49.3% | -1.6% |
| Debt to Equity | 0.00x | 0.49x | 0.54x | 0.82x | 2.71x | 0.14x | 0.19x | 0.19x | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Singbao International Co Ltd dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Jul 11, 2024
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | TWD 22.2M | 0.50 | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Singbao International Co Ltd
- Insiders 62.10%
- Institutions 0.00%
- Public & others 37.90%
- Shares outstanding 49.3M
- Free float 24.0M
Singbao International Co Ltd company profile
- Company name
- Singbao International Co Ltd
- Ticker
- 6130.TWO
- ISIN
- TW0006130008
- Exchange
- Taiwan OTC Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Fiscal year end
- December
- Address
- No. 188, Nanjing East Road, Taipei, Taiwan, 105052
- Phone
- 886 2 2713 2100
- Website
- singbao.com
About Singbao International Co Ltd
Shangya Technology Co., Ltd. engages in the generic drugs and solar power generation businesses in Taiwan and Asia. The company wholesales Chinese and Western medicines, medical equipment, and beauty and hair care products; and onrito, lixin fumitation, lufuxing film-coated, amperex film coating, leverb-coated, triton film-coated, special core stabilized, tanlipo film-coated, inhibitory film-coated, yoyo flat mouth dissolved, and binlishu film-coated tablet, as well as pain relief capsules and yue shi tong injection. It is also involved in the research, development, production, and sale of wireless communication integrated circuits, satellite positioning system integrated circuits, and portable product ICs. The company was formerly known as Singbao International Co. Ltd and changed its name to Shangya Technology Co., Ltd. in July 2023. Shangya Technology Co., Ltd. was founded in 1994 and is based in Taipei, Taiwan.
Singbao International Co Ltd management
1- Mr. Qian Kui HuangChairman & GM